Please login to the form below

Not currently logged in
Email:
Password:

Isis

This page shows the latest Isis news and features for those working in and with pharma, biotech and healthcare.

Biogen buys into Ionis' nusinersen after positive phase III trial

Biogen buys into Ionis' nusinersen after positive phase III trial

The trial has now been halted and all placebo patients have been offered the option to swap over to treatment with the active drug (also known as ISIS-SMNRx), which is ... A second phase III trial called CHERISH is also ongoing and is due to generate

Latest news

More from news
Approximately 10 fully matching, plus 36 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    Building on the existing antisense relationship that was forged through its original deal with Isis [for 5 cancer targets] signed in December 2012 AstraZeneca invested further with an upfront fee of ... Exclusive licence. 90. Isis. AZ. Addition to Dec

  • Pharma deals in May 2015 Pharma deals in May 2015

    245. Isis/ Bayer. Licence agreement. Anticoagulant ISIS FXIRx for prevention of thrombosis in P2.

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Strategic collaboration. 1, 000. Isis/ Janssen. Antisense drugs to treat autoimmune disorders of the GI tract - local and oral therapies (3 programmes).

  • Pharma deals during January 2015 Pharma deals during January 2015

    A $35m payment went in an upfront to Isis as part of its $835m headline deal for a collaboration to discover and develop antisense drugs in autoimmune disorders in the GI

  • Pharma deals during November 2014 Pharma deals during November 2014

    AZ also announced a strategic alliance with ISIS Pharmaceuticals building on an existing collaboration between the companies, in the area of antisense oligonucleotide-based therapeutics and RNA biology.

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics